Fungal infections are often neglected by political and social communities. However, they affect more than a billion people, resulting in approximately 11.5 million life-threatening infections and more than 1.5 million deaths annually. India is currently facing a severe second wave of COVID-19 infections and their complications. One of the severe complications arising is mucormycosis and other fungal infections. Some invasive fungal infections carry a high risk of mortality. Hence, timely diagnosis and treatment are essential in curing fungal infections.
Objective: Doctors’ perception and management of fungal infections
A total of 879 doctors participated in the survey, including 47% others, 24% general practitioners, 8% dentist, 5% otolaryngologist, 4% pharmacologist, 3% anesthesiologist, 3% ayurveda, 3% obstetrician & gynecologist and 3% pediatrics.
- Around 52% of the doctors responded that Liposomal Amphotericin B is the choice of medication for antifungal prophylaxis
- A majority of the doctors, 37% responded that symptoms are the choice of diagnosis for fungal infections before starting treatment
- Around 46% of the doctors responded that they frequently come across patients with localized fungal infections
- Around 65% of doctors responded that they commonly observe localized fungal infections on the skin
- Around 54% of doctors responded that Posaconazole is an alternative treatment during the shortage of Amphotericin B amidst the increasing cases of mucormycosis in COVID-19 patients
- Around 34% of the doctors responded that other than steroid overuse, uncontrolled comorbid conditions have contributed to the recent mucormycosis outbreak
- Around 40% of the doctors responded that in case of invasive aspergillosis, liposomal amphotericin B is the first choice
- Around 41% of the doctors responded that nephrotoxicity is the adverse effect of commonly prescribed antifungals
- Around 44% of the doctors responded that surgery or minor procedure is required sometimes to treat fungal infections
- Around 40% of the doctors responded that they rarely recommend measuring serum antifungal levels in a patient
Our survey revealed that, as doctors frequently come across patients with localized fungal infections the diagnosis is based on the symptoms. Around 52% of the doctors responded that Liposomal Amphotericin B is the first choice of medication for antifungal prophylaxis. Amidst the increase in mucormycosis in Covid 19 patients, there is a shortage of Amphotericin B. In such a scenario, 54% of doctors recommended Posaconazole as the alternative treatment. It has been reported that Posaconazole is successfully used in combination or as second-line therapy for the treatment of mucormycosis. Around 34% of the doctors responded that uncontrolled comorbidities contributed to the mucormycosis outbreak. According to evidence, apart, from comorbidities, mainly diabetes, mucormycosis affects immunosuppressed patients due to steroids or patients with a prolonged ICU stay. Physicians should provide patients with adequate knowledge on diabetes management, personal hygiene and probable symptoms of mucormycosis.
To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com